SRCM
IBRX icon

Signature Resources Capital Management’s ImmunityBio IBRX Stock Holding History

Signature Resources Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,000
Closed -$2.46K – 700
2025
Q3 		$2.46K Buy
+1,000
New +$2.58K ﹤0.01% 407

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Signature Resources Capital Management's IBRX Position: Q4 2025 in Review

Signature Resources Capital Management sold out of ImmunityBio (IBRX) in Q4 2025, closing a stake of 1,000 shares — an estimated $2.46K sold.

Signature Resources Capital Management first reported a position in IBRX in Q3 2025 and held it in 1 quarter. The position peaked at $2.46K in Q3 2025. 278 funds tracked by Wall St. Rank hold IBRX as of Q4 2025.

  • Signature Resources Capital Management reported no remaining ImmunityBio position as of Q4 2025 after selling out during the quarter.
  • Signature Resources Capital Management sold 1,000 ImmunityBio shares in Q4 2025, an estimated $2.46K.
  • Signature Resources Capital Management first reported a position in ImmunityBio in Q3 2025 and held it in 1 quarter.
  • Signature Resources Capital Management's ImmunityBio position peaked at $2.46K in Q3 2025.
  • 278 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2025.

Based on Signature Resources Capital Management's 13F filing for Q4 2025, filed 21 Jan 2026.